Proportion of treatment effect (PTE) explained by a surrogate marker

被引:29
作者
Chen, C [1 ]
Wang, HW [1 ]
Snapinn, SM [1 ]
机构
[1] Merck Res Labs, W Point, PA 19486 USA
关键词
causal effect; decomposition; information separation; surrogate endpoint;
D O I
10.1002/sim.1575
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
In time-varying covariate analysis of clinical survival data, it is often of interest to estimate the proportion of treatment effect (PTE), along with its confidence intervals, explained by a surrogate marker. The conventional procedure for such an analysis fits data into two working models separately to estimate the treatment effects before and after adjustment of the covariate. The construction of confidence intervals for the PTE under the conventional procedure lacks support by standard statistical software such as SAS, and could be very computationally demanding even after the support is available in the future. To overcome this problem, we propose a new procedure to simplify the computation. Under the new procedure, the treatment effects before and after adjustment of the covariate are simultaneously estimated from a single model. More important than saving computational effort, the new procedure can also be effectively applied to multiple-covariate models for the decomposition of overall treatment effect and for the comparison of PTE among several surrogate markers. The new procedure is applied to the motivating data example from the LIFE study, and demonstrates flexibility that the conventional procedure currently lacks. Copyright (C) 2003 John Wiley Sons, Ltd.
引用
收藏
页码:3449 / 3459
页数:11
相关论文
共 20 条
[1]  
Andersen P K, 1992, Stat Methods Med Res, V1, P297, DOI 10.1177/096228029200100305
[2]   COX REGRESSION-MODEL FOR COUNTING-PROCESSES - A LARGE SAMPLE STUDY [J].
ANDERSEN, PK ;
GILL, RD .
ANNALS OF STATISTICS, 1982, 10 (04) :1100-1120
[3]   Angiotensin blockade for hypertension: a promise fulfilled [J].
Brunner, HR ;
Gavras, H .
LANCET, 2002, 359 (9311) :990-992
[4]   Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].
Dahlöf, B ;
Devereux, RB ;
Kjeldsen, SE ;
Julius, S ;
Beevers, G ;
de Faire, U ;
Fyhrquist, F ;
Ibsen, H ;
Kristiansson, K ;
Lederballe-Pedersen, O ;
Lindholm, LH ;
Nieminen, MS ;
Omvik, P ;
Oparil, S ;
Wedel, H .
LANCET, 2002, 359 (9311) :995-1003
[5]   Perspective: Validating surrogate markers - Are we being naive? [J].
DeGruttola, V ;
Fleming, T ;
Lin, DY ;
Coombs, R .
JOURNAL OF INFECTIOUS DISEASES, 1997, 175 (02) :237-246
[6]  
Fieller EC., 1940, Suppl J R Stat Soc, V7, P1, DOI DOI 10.2307/2983630
[7]   Time-dependent covariates in the Cox proportional-hazards regression model [J].
Fisher, LD ;
Lin, DY .
ANNUAL REVIEW OF PUBLIC HEALTH, 1999, 20 :145-157
[8]   Surrogate end points in clinical trials: Are we being misled? [J].
Fleming, TR ;
DeMets, DL .
ANNALS OF INTERNAL MEDICINE, 1996, 125 (07) :605-613
[9]   STATISTICAL VALIDATION OF INTERMEDIATE END-POINTS FOR CHRONIC DISEASES [J].
FREEDMAN, LS ;
GRAUBARD, BI ;
SCHATZKIN, A .
STATISTICS IN MEDICINE, 1992, 11 (02) :167-178
[10]   Confidence intervals and statistical power of the 'Validation' ratio for surrogate or intermediate endpoints [J].
Freedman, LS .
JOURNAL OF STATISTICAL PLANNING AND INFERENCE, 2001, 96 (01) :143-153